Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

This study has been completed.

First Received: October 30, 2006 Last Updated: February 11, 2008 History of Changes

Sponsored by:	Myriad Pharmaceuticals
Information provided by:	Myriad Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00394446

Purpose

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Condition	Intervention	Phase
Refractory Solid Tumors	Drug: MPC-6827	Phase I

MedlinePlus related topics: Cancer

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study
Official Title:	Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.

Further study details as provided by Myriad Pharmaceuticals:

Primary Outcome Measures:

Maximum Tolerated Dose [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Pharmacokinetics [ Time Frame: 22 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Enrollment:	48
Study Start Date:	March 2005
Study Completion Date:	February 2008
Primary Completion Date:	April 2007 (Final data collection date for primary outcome measure)

Intervention Details:

2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00394446

Locations

United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112

Sponsors and Collaborators

Myriad Pharmaceuticals

Investigators

Study Director:

Margaret Yu, MD

Myriad Pharmaceuticals

More Information

No publications provided

Responsible Party:	Myriad Pharmaceuticals, Inc. ( Margaret Yu, MD / Director of Clinical Research )
Study ID Numbers:	MPC6827-04-001
Study First Received:	October 30, 2006
Last Updated:	February 11, 2008
ClinicalTrials.gov Identifier:	NCT00394446 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Myriad Pharmaceuticals:

Solid Tumors
Refractory
Brain

ClinicalTrials.gov processed this record on May 07, 2009